<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801086</url>
  </required_header>
  <id_info>
    <org_study_id>MITO 02-03</org_study_id>
    <nct_id>NCT00801086</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain</brief_title>
  <official_title>Phase II Double-Blind, Placebo-Controlled Study of the Safety and Preliminary Effectiveness of MTS-01 for the Prevention of Alopecia Induced by Whole Brain Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitos Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitos Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hair loss occurs commonly as a result of radiotherapy administered to the brain, and this can
      contribute to the distress and social isolation of patients with advanced cancer. In this
      study a topical gel will be applied directly to the scalp during each dose of radiotherapy.
      The goal is to determine to what extent the experimental drug is successful in lessening the
      hair loss.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness will be based on a comparison of hair retention scores between MTS-01 and placebo.</measure>
    <time_frame>Assessments occur weekly during treatment and follow-up assessments occur for 12 weeks following treatment.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Alopecia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MTS-01 (7% Tempol gel)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7% (w/v) Tempol alcohol-based gel (MTS-01)</intervention_name>
    <description>200mL gel applied daily prior to radiation dose and removed immediately thereafter.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alcohol-based gel</intervention_name>
    <description>200mL gel applied daily prior to radiation dose and removed immediately thereafter</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic cancer to the brain for which palliative whole brain radiotherapy is
             recommended.

          -  Hair that covers the scalp and is at least 1/4 inch in length

        Exclusion Criteria:

          -  Receiving chemotherapy known to cause alopecia within 60 days of study or during the
             study.

          -  Pre-existing alopecia

          -  Previous brain radiotherapy

          -  scalp metastases or scalp wounds

          -  use of hair dyes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Metz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Holt</last_name>
      <phone>520-694-6000</phone>
      <phone_ext>2970</phone_ext>
    </contact>
    <investigator>
      <last_name>Baldassarre Stea, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Smith, RN</last_name>
      <phone>215-662-6694</phone>
    </contact>
    <investigator>
      <last_name>Jim Metz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2008</study_first_posted>
  <last_update_submitted>December 2, 2008</last_update_submitted>
  <last_update_submitted_qc>December 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Louis Habash/ President and CEO</name_title>
    <organization>Mitos Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Alopecia</keyword>
  <keyword>Hair loss</keyword>
  <keyword>Radiation</keyword>
  <keyword>Whole brain radiotherapy</keyword>
  <keyword>Radiation-induced alopecia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Tempol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

